modelN03AX26
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | Fenfluramine | |
| ATC code: | N03AX26 | route: | oral |
| compartments: | 1 | |
| dosage: | 60 | mg |
| volume of distribution: | 14.1 | L |
| clearance: | 119 | mL/min |
| other parameters in model implementation | ||
Fenfluramine is an amphetamine derivative formerly used as an appetite suppressant for obesity management. It was withdrawn from the market due to concerns about valvular heart disease and pulmonary hypertension. Currently, fenfluramine is approved (under restricted conditions) for adjunctive treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in pediatric patients.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.
References
Mittur, A, et al., & Boyd, B (2024). Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine. Journal of clinical pharmacology 64(7) 887–898. DOI:10.1002/jcph.2431 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38523492
Imbeault, P, et al., & Tremblay, A (2002). Increase in plasma pollutant levels in response to weight loss is associated with the reduction of fasting insulin levels in men but not in women. Metabolism: clinical and experimental 51(4) 482–486. DOI:10.1053/meta.2002.31338 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11912558
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)